Transplantation and tumors.
Morales
J M
JM
Servicio de Nefrología, Hospital Doce de Octubre, Madrid. jmorales@h12o.es
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D046148:Donor Selection / Q000592:standards*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015994:Incidence; D008232:Lymphoproliferative Disorders / Q000453:epidemiology / Q000209:etiology / Q000821:virology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D016377:Organ Transplantation / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D012086:Reoperation; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000453:epidemiology / Q000209:etiology; D020123:Sirolimus / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000453:epidemiology / Q000209:etiology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D014019:Tissue Donors; D019139:Tumor Escape
D020533:Angiogenesis Inhibitors; D007166:Immunosuppressive Agents; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus